arXiv:2611.03844v1 Announce Type: new Abstract: Therapeutic antibody development is often framed as comprising two discrete stages: initial discovery of novel binders followed by iterative optimization to refine these hits into therapeutic-grade molecules. Models and methods often reflect these stages, with generative structure models applied to discovery and probabilistic black-box optimization methods applied to refinement. Here we propose to unify these stages by smoothly transitioning a generative discovery model into iterative optimization, allowing the handoff between the structure-based prior and supervision from wet lab data to be guided by the posterior uncertainty of a probabilistic surrogate.
Machine Learning · 2026-11-04
Probabilistic Steering of Generative Priors for Lab-in-the-Loop Antibody Optimization
arXiv:2611.03844v1 Announce Type: new Abstract: Therapeutic antibody development is often framed as comprising two discrete stages: initial discovery of novel binders followed by iterative optimization to refine these hits into therapeutic-grade molecules.
Source and attribution
This is an attributed editorial digest. For the complete study and original reporting, follow the source link.
Reader feedback
0 likes · 0 dislikes